COSMOS Pharmaceutical Corporation
【Cosmos Pharmaceutical】2026 Financial Results | Sales of ¥1,009.9 billion (YoY 8.7% increase)
Cosmos Pharmaceutical achieved sales of ¥1,009.9 billion (up 8.7% YoY) and operating profit of ¥4.253 billion (up 4.8%) for the fiscal year ending May 2026. The company expanded its store network and closed some stores, increasing net assets to ¥283.7 billion. It also signals continued store expansion and steady performance in the upcoming period.
Key Figures
- Sales: ¥1,009.9 billion (YoY 8.7% increase)
- Net Assets: ¥283.7 billion (up 10.2% compared to previous period)
- Number of Stores: 1,708 stores (105 new stores opened, 6 stores closed)
AI要約
Performance Overview
For the fiscal year ending May 2026, Cosmos Pharmaceutical reported sales of ¥1,009.9 billion, operating profit of ¥4.253 billion, and net income of ¥3.046 billion, all showing increases compared to the previous corresponding period. Store openings resulting from active expansion policies increased the total number of stores to 1,708, strengthening regional presence. Financially, net assets grew to ¥283.7 billion, maintaining a stable financial foundation.
Outlook and Impact on Shareholders
For the next fiscal year (ending May 2027), sales are forecasted at ¥1,190.0 billion, with net income of ¥3.07 billion. The company will continue expanding its store network and promoting low-price sales. An annual dividend of ¥84 is planned, continuing shareholder returns. Through proactive store expansion and prudent management, Cosmos Pharmaceutical maintains an attractive growth platform for investors.
Cosmos Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
